512 related articles for article (PubMed ID: 11257030)
1. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
Chand P; Bantia S; Kotian PL; El-Kattan Y; Lin TH; Babu YS
Bioorg Med Chem; 2005 Jun; 13(12):4071-7. PubMed ID: 15911320
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
[TBL] [Abstract][Full Text] [Related]
7. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
9. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
Sidwell RW; Smee DF; Huffman JH; Barnard DL; Bailey KW; Morrey JD; Babu YS
Antimicrob Agents Chemother; 2001 Mar; 45(3):749-57. PubMed ID: 11181355
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Boivin G; Goyette N
Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
[TBL] [Abstract][Full Text] [Related]
11. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
12. [Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
Kaji M
Nihon Rinsho; 2003 Nov; 61(11):1975-9. PubMed ID: 14619441
[TBL] [Abstract][Full Text] [Related]
13. Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Smith BJ; McKimm-Breshkin JL; McDonald M; Fernley RT; Varghese JN; Colman PM
J Med Chem; 2002 May; 45(11):2207-12. PubMed ID: 12014958
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
15. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.
Smee DF; Huffman JH; Morrison AC; Barnard DL; Sidwell RW
Antimicrob Agents Chemother; 2001 Mar; 45(3):743-8. PubMed ID: 11181354
[TBL] [Abstract][Full Text] [Related]
16. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
Yen HL; Monto AS; Webster RG; Govorkova EA
J Infect Dis; 2005 Aug; 192(4):665-72. PubMed ID: 16028136
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of 6-acetamido-5-amino- and -5-guanidino-3, 4-dehydro-N-(2-ethylbutyryl)- 3-piperidinecarboxylic acids related to zanamivir and oseltamivir, inhibitors of influenza virus neuraminidases.
Shitara E; Nishimura Y; Nerome K; Hiramoto Y; Takeuchi T
Org Lett; 2000 Nov; 2(24):3837-40. PubMed ID: 11101432
[TBL] [Abstract][Full Text] [Related]
18. Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors.
Cross J; Wedekind CA
Med Health R I; 2001 Jun; 84(6):209-11. PubMed ID: 11434154
[No Abstract] [Full Text] [Related]
19. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
